### H3B-6545

**Cat. No.:** HY-112596  
**CAS No.:** 2052130-80-8  
**Molecular Formula:** C₃₀H₂₉F₄N₅O₂  
**Molecular Weight:** 567.58  
**Target:** Estrogen Receptor/ERR  
**Pathway:** Others  
**Storage:** Please store the product under the recommended conditions in the COA.

#### BIOLOGICAL ACTIVITY

<table>
<thead>
<tr>
<th>Description</th>
<th>H3B-6545 is an oral, selective estrogen receptor covalent antagonist (SERCA).</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC₅₀ &amp; Target</td>
<td>Estrogen receptor[^1]</td>
</tr>
<tr>
<td><strong>In Vitro</strong></td>
<td>H3B-6545 is a highly selective small molecule that potently antagonizes wild-type and mutant ERα in biochemical and cell based assays. In vitro comparisons with standard of care and other experimental agents confirm increased cell potency of H3B-6545 under continuous as well as washout treatment conditions[^1]. H3B-6545, a member of a novel class of ERα antagonists refer to as selective ER covalent antagonist (SERCA), which inactivates both wild-type and mutant ERα by targeting CS30 and enforcing a unique antagonist conformation. H3B-6545 is a first-in-class selective ER covalent antagonist (SERCA). H3B-6545 inhibits ERαWT activity and growth of ERαWT-positive breast cancer lines. H3B-6545 potently inhibits ERαWT activity and suppresses proliferation of ERαWT-positive breast cancer lines. With GI₅₀s of 0.3-0.4, 1.0, 0.5, 5.2, and 0.2 nM for MCF7, HCC1428, BT483, T47D and CAMA-1 cell lines[^1].</td>
</tr>
<tr>
<td><strong>In Vivo</strong></td>
<td>In vivo, once daily oral dosing of H3B-6545 shows potent activity and superior efficacy to fulvestrant in the MCF-7 xenograft model with maximal antitumor activity at doses &gt;10x below the maximum tolerated dose in mice. In addition, H3B-6545 shows superior antitumor activity to Tamoxifen and Fulvestrant in patient derived xenograft models of estrogen receptor positive breast cancer including models carrying ERα mutations in rat and monkeys, H3B-6545 is well tolerated across a broad dose range and at exposures that significantly exceed those required for efficacy in mouse xenograft models[^1].</td>
</tr>
</tbody>
</table>

#### CUSTOMER VALIDATION


See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

#### REFERENCES

[2]. Manav Korpel, et al. Development of a First-in-Class Oral Selective ER Covalent Antagonist (SERCA) for the Treatment of ER$\alpha^{WT}$ and ER$\alpha^{MUT}$ Breast Cancer.